2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Value, Diseases, Bleeding and Clotting, Immunology, Infectious Diseases, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

1606 Combination of mitoxantrone hydrochloride liposome with CLAG regimen in patients with relapsed or refractory acute myeloid leukemia: analysis of an expanded prospective single-arm study

Kai Wan, Wen Qin, MD2, Xue Liu3, Xiao Han4, Hongju Yan5, Zhang Mengyun6, Dongfeng Zeng, PhD7, Li Wang8, Qianwei Lu9, Cheng Zhang, MD10, Xi Zhang, MD11
1 Xinqiao Hospital Army Medical University, Chongqing, China
2 Xinqiao Hospital Army Medical University, Chongqing, China
3 Xinqiao Hospital Army Medical University, Chongqing, China
4 Xinqiao Hospital Army Medical University, Chongqing, China
5 Xinqiao Hospital Army Medical University, Chongqing, China
6 Xinqiao Hospital Army Medical University, Chongqing, China
7 Army Medical University Army Characteristic Medical Center (Daping Hospital), Chongqing, China
8 The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
9 The Ninth People's Hospital of Chongqing, Chongqing, China
10 Xinqiao Hospital Army Medical University, Chongqing, China
11 Xinqiao Hospital Army Medical University, Chongqing, China

Background: Relapsed or refractory acute myeloid leukemia (R/R AML) carries a poor prognosis with currently no standard salvage therapy. Intensive chemotherapy followed by allogeneic hematopoietic cell transplantation (allo-HSCT) represents the most common treatment approach. The CLAG regimen [cladribine, cytarabine, and granulocyte colony-stimulating factor (G-CSF)] with or without mitoxantrone is a commonly used salvage regimen. Mitoxantrone hydrochloride liposome (Lipo-MIT), the first approved nano-formulation of mitoxantrone, has demonstrated improved pharmacokinetics and shown anti-leukemic activity in early-phase AML studies. We previously reported preliminary findings of Lipo-MIT combined with CLAG at ASH 2025. Here we present updated results from this trial (ChiCTR2400086291).

Methods: Eligible patients with confirmed diagnosis of R/R AML, excluding acute promyelocytic leukemia (APL), were enrolled. Patients received the Lipo-MIT (18 mg/m2, day 1) combined with CLAG (cladribine 5 mg/m2 days 1-5, cytarabine 1 g/m2 days 1-5, G-CSF 300 μg days 0-5) every 4 weeks for up to 2 cycles. The primary endpoint was the composite complete remission (CRc) rate. Secondary endpoints were overall response rate (ORR), survival, measurable residual disease (MRD) negative rate, and safety.

Results: At data cut-off on July 17, 2026, 43 patients with R/R AML were enrolled. The median age was 46 years (range, 10-64), and 55.8% were male. Among them, 24 (55.8%) had refractory disease, 19 (44.2%) had relapsed disease, and 4 (9.3%) had secondary AML. ELN 2022 risk stratification revealed 25.6% favorable, 34.9% intermediate, and 39.5% adverse. Common mutations included CEBPA (20.9%, 9/43), TP53 (7.0%, 3/43), ASXL1 (7.0% 3/43), and RUNX1 (7.0%, 3/43).

Among 43 efficacy-evaluable patients, the best CRc rate was 62.8% (27/43; 95% CI, 46.7%-77.0%), and the ORR was 69.8% (30/43; 95% CI, 53.9%-82.8%). The flow cytometric MRD negative rate among CRc patients with evaluable results was 70.6% (12/17).With a median follow-up of 4.5 months (range 0.6-35.0), the 6-month relapse-free survival (RFS) and overall survival (OS) rates were 68.8% (95% CI, 42.9-84.7) and 84.7% (95% CI, 64.0-94.0), respectively. Among the 27 CRc patients, 14 (51.9%) proceeded to HSCT (13 allogeneic). The 6-month OS rate was 92.9% (95% CI, 59.1–99.0) in the transplant group, compared with 66.7% (95% CI, 19.5-90.4) in the non-transplant group (N=13). 

Hematological toxicities were the main treatment-related adverse events (TRAEs). In patients with CRc, median durations of neutropenia (<0.5×109/L) and thrombocytopenia (<25×109/L) were 28.5 days (range, 14-57) and 20 days (range, 3-57). Common grade 3/4 non-hematological TRAEs included febrile neutropenia (69.8%), infection (51.2%), and sepsis (14.0%).

Conclusions: The CLAG-M regimen continues to show promising efficacy and manageable safety in R/R AML, with encouraging post-transplant survival supporting its role as an effective bridge to allo-HSCT.

Xiao Han: No relevant conflicts of interest to declare.